Insider Transactions in Q1 2021 at Cyclo Therapeutics, Inc. (CYTH)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2021
|
Jeffrey Tate Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+6.86%
|
$14,000
$7.5 P/Share
|
|
Mar 29
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
3,000
+2.4%
|
$21,000
$7.5 P/Share
|
|
Mar 29
2021
|
Sharon Hemond Hrynkow Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+5.17%
|
$7,000
$7.46 P/Share
|
|
Mar 29
2021
|
Joshua M Fine Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50
+0.3%
|
$350
$7.4 P/Share
|
|
Mar 29
2021
|
Markus Sieger Director |
BUY
Open market or private purchase
|
Direct |
10,000
+12.88%
|
$80,000
$8.1 P/Share
|
|
Mar 05
2021
|
Randall M. Toig Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
10,000
+18.49%
|
$50,000
$5.0 P/Share
|
|
Jan 26
2021
|
Markus Sieger Director |
BUY
Open market or private purchase
|
Direct |
2,201
+3.68%
|
$13,206
$6.6 P/Share
|
|
Jan 25
2021
|
Markus Sieger Director |
BUY
Open market or private purchase
|
Direct |
7,799
+4.67%
|
$46,794
$6.3 P/Share
|
|
Jan 13
2021
|
Joshua M Fine Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+37.24%
|
-
|
|
Jan 13
2021
|
N Scott Fine Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+8.36%
|
-
|
|
Jan 13
2021
|
Jeffrey Tate Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+28.44%
|
-
|
|
Jan 13
2021
|
Sharon Hemond Hrynkow Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+36.56%
|
-
|
|
Jan 13
2021
|
Michael Eric Lisjak Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+44.64%
|
-
|